



**WHEREFORE**, Novo Nordisk Defendants pray that their motion be granted, and that they be granted until November 14, 2023, within which to file an answer or otherwise responsive pleadings.

Respectfully submitted,

**ADAMS AND REESE LLP**

/s/ Diana Cole Surprenant

E. Paige Sensenbrenner (LA Bar No. 18429)

Diana Cole Surprenant (LA Bar No. 33399)

701 Poydras Street

Suite 4500

New Orleans, LA 70139

Tel: (504) 581-3234

Email: paige.sensenbrenner@arlaw.com

Email: diana.surprenant@arlaw.com

AND

**DLA PIPER LLP (US)**

/s/ Loren H. Brown

Loren H. Brown (*pro hac vice forthcoming*)

1251 Avenue of the Americas

27th Floor

New York, NY 10020-1104

Tel: (212) 335-4846

Email: loren.brown@us.dlapiper.com

*Attorneys for Defendants Novo Nordisk US Holdings Inc., Novo Nordisk US Commercial Holdings Inc., Novo Nordisk Inc., Novo Nordisk Research Center Seattle, Inc., and Novo Nordisk Pharmaceutical Industries, LP*